Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca

NCT04921904 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Esophageal Adenocarcinoma
Metastatic Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Abemaciclib
DRUG: Ramucirumab

Sponsor

Baylor Research Institute